VNRX Financials: VolitionRX Ltd AI Analysis



Financials

VNRX Financial

VolitionRX Ltd

$0.14

-9.38%

$-0.01

As of today:Apr 23, 14:18:33 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.1577

Open

$0.1571

Day's Range

$0.14 - $0.1571

52 week range

$0.1429 - $0.94

Volume

3.5M

Avg.Volume

8.4M

Dividend yield

EPS (TTM)

-0.22

Market Cap

$22.6M

What is VNRX?

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Features

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

VNRX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	1	0	0	0	0	0
Revenue Growth (YoY)	0%	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	13	2	3	3	3	3
Research & Development	9	2	2	2	2	2
Operating Expenses	23	5	5	6	5	5
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-23	-6	-5	-6	-5	-5
Income Tax Expense	--	--	--	--	--	--
Net Income	-23	-6	-5	-6	-5	-5
Net Income Growth	-12%	20%	0%	0%	-38%	-38%
Shares Outstanding (Diluted)	120.98	120.98	108.21	102.65	96.53	93.62
Shares Change (YoY)	28.99%	28.99%	23%	24%	18%	18%
EPS (Diluted)	-0.19	-0.05	-0.04	-0.06	-0.05	-0.06
EPS Growth	-32%	-16%	-25%	-28%	-45%	-43%
Free Cash Flow	-19	-5	-3	-6	-4	-5
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	-2,100%	0%	0%	0%	0%	0%
Profit Margin	-2,300%	0%	0%	0%	0%	0%
Free Cash Flow Margin	-1,900%	0%	0%	0%	0%	0%
EBITDA	-21	-4	-5	-6	-5	-5
EBITDA Margin	-2,100%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-21	-4	-5	-6	-5	-5
EBIT Margin	-2,100%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	--

Follow-Up Questions

What are VolitionRX Ltd's key financial statements?



According to the latest financial statement (Form-10K), VolitionRX Ltd has a total asset of $0, Net loss of $0

What are the key financial ratios for VNRX?



VolitionRX Ltd's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is VolitionRX Ltd's revenue broken down by segment or geography?



VolitionRX Ltd largest revenue segment is Blood Tests, at a revenue of 598,457 in the most earnings release.For geography, United States is the primary market for VolitionRX Ltd, at a revenue of 775,302.

Is VolitionRX Ltd profitable?



no, according to the latest financial statements, VolitionRX Ltd has a net loss of $0

Does VolitionRX Ltd have any liabilities?



no, VolitionRX Ltd has liability of 0

How many outstanding shares for VolitionRX Ltd?



VolitionRX Ltd has a total outstanding shares of 0

VolitionRX Ltd (VNRX) Financial

VNRX Stock Price Chart